Current status of thrombolytic therapy. 1985

J M Porter, and L M Taylor

The optimal role of thrombolytic therapy in clinical practice has not been defined precisely. A review of available information indicates that such therapy may be useful in a small number of carefully selected patients with deep vein thrombosis and/or pulmonary emboli. The superiority of thrombolytic therapy over conventional surgery for arterial thrombi has not been convincingly demonstrated. Available evidence suggests such therapy should be reserved for those conditions in which surgery may be expected to have a poor outcome or be associated with a high incidence of complications. Preliminary information suggests thrombolytic therapy may be of benefit in selected patients with acute myocardial infarction.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D011655 Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS. Pulmonary Thromboembolism,Thromboembolism, Pulmonary,Embolism, Pulmonary,Embolisms, Pulmonary,Pulmonary Embolisms,Pulmonary Thromboembolisms,Thromboembolisms, Pulmonary
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J M Porter, and L M Taylor
November 1975, The New England journal of medicine,
J M Porter, and L M Taylor
October 1970, The Johns Hopkins medical journal,
J M Porter, and L M Taylor
January 1978, Heart & lung : the journal of critical care,
J M Porter, and L M Taylor
September 1964, Geriatrics,
J M Porter, and L M Taylor
June 1988, The New England journal of medicine,
J M Porter, and L M Taylor
June 1988, The New England journal of medicine,
J M Porter, and L M Taylor
August 1997, Australian and New Zealand journal of medicine,
J M Porter, and L M Taylor
September 1996, European heart journal,
J M Porter, and L M Taylor
January 1991, Texas Heart Institute journal,
J M Porter, and L M Taylor
November 1991, Journal of the Indian Medical Association,
Copied contents to your clipboard!